secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001048477-25-000104
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q3 net loss $31M vs income $106M YoY; revenue +4% to $776M; guidance raised
--------------------------------------------------------------------------------

- GAAP net loss of $31M (diluted EPS -$0.16) vs income $106M ($0.55) in Q3 2024, due to $221M IPR&D charge from Inozyme acquisition.
- Non-GAAP income fell to $22M ($0.12 EPS) from $178M ($0.91), reflecting the Inozyme charge and SG&A investments.
- Total revenue $776M (+4% YoY); VOXZOGO $218M (+15%), PALYNZIQ $109M (+20%), but ALDURAZYME -24% and NAGLAZYME -8%.
- Full-year 2025 total revenue guidance raised at midpoint; VOXZOGO outlook reaffirmed at $900M-$935M.
- Company pursuing options to divest ROCTAVIAN (hemophilia A gene therapy), including out-licensing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847725000104/0001048477-25-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847725000104/bmrn-20251027.htm
  HTML page:      https://secwatch.observer/filing/0001048477-25-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer